

# **Minutes**

Date Wednesday, 03/07/2024

Time 9:00 AM

To Committee Members

At Virtual via MS Teams

Subject AWERB 3Rs Committee

our Ref Doc.AWERB.3Rs.03.07.24

AWERB 3Rs Committee :
Attendees:
Minutes –
Apologies:

### 1. Minutes

The minutes from the previous meeting held on 5<sup>th</sup> June 2024 were approved.

## 2. Matters arising

There were no matters arising.

## 3. Retrospective Reviews and Assessments

- New treatment strategies for myocardial infarction and aortic aneurysm - RA

The committee discussed the following:

- The need for further information in Section 2.4 regarding the adverse effects and reporting.
- The need for further information in Section 2.6 regarding the impact of the procedures detailed.
- The need for further information in Section 2.11.
- Section 3.5 needs to be completed.
- Further clarity was needed regarding systems mentioned in Section 3.8.
- Whether specific methods mentioned in Section 3.10 that were not previously used are to be included in the new licence.
- Section 5.2 needs to be completed.



(b)	- Regeneration in the	nervous system - RA
· ·	3	<b>,</b>

The committee discussed the following:

Further consideration given to the questions in Section 2.9 based on the changes mentioned.

### 4. Project Licence Applications - New / Amendments

- - The committee did not raise any comments
- Tuberculosis pathogenesis & treatment in zebrafish and medaka Protocol 5 SS Amendment

The committee discussed the following:

Further justification required for Protocol 5, Step 2.

## (c) Standard Condition 18 Reports

discussed the reports from May 2024. There were 37 reports, involving 116 animals in total. The majority of these reports were for tumors.

## (d) 3Rs information/reports

Nothing to report.

## (e) Minutes of the AOC meeting

The minutes from the meeting held on 24/05/2024 were noted.

### (f) Minutes of the AWERB Standing meeting

The minutes were not available.

## (g) Any Other Business

discussed the RSPCA roadmap sessions. They were very successful, with lots of engagement during the sessions and feedback has been positive. A process for inclusion of the learnings into this committee is being considered.

Date of next meeting: 7<sup>th</sup> August 2024 via MS Teams.